An Exceptional Responder to Nivolumab in Metastatic Non-Small-Cell Lung Cancer: A Case Report and Literature Review of Long-Term Survivors

BACKGROUND: Exceptional responders to immune checkpoint inhibitors in metastatic non-small-cell lung cancer (NSCLC) are rare. Furthermore, the optimal duration of immunotherapy in patients who achieve complete remission and the benefit of rechallenge after recurrence remain unknown. Studying the cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Baseri, Babak, Samra, Bachar, Tam, Eric, Chiu, Edwin, Leaf, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6915153/
https://www.ncbi.nlm.nih.gov/pubmed/31885970
http://dx.doi.org/10.1155/2019/1816472

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6915153/
https://www.ncbi.nlm.nih.gov/pubmed/31885970
http://dx.doi.org/10.1155/2019/1816472

Ejemplares similares